Evaluation of 7-O-galloyl-D-sedoheptulose, isolated from Corni Fructus, in the adipose tissue of type 2 diabetic db/db mice

Fitoterapia

Volumn 89, Issue 1, 2013, Pages 131-142

  Park, Chan Hum ^a   Tanaka, Takashi ^b   Yokozawa, Takako ^a,c  

^a UNIVERSITY OF TOYAMA   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c Pusan National University   (South Korea)

Author keywords

7 O galloyl D sedoheptulose; Adipose tissue; Apoptosis; Inflammation; Oxidative stress; Type 2 diabetes

Indexed keywords

7 O GALLOYL DELTA SEDOHEPTULOSE; ADIPONECTIN; ANTIDIABETIC AGENT; C PEPTIDE; CASPASE 3; CYCLOOXYGENASE 2; CYTOCHROME C; FATTY ACID; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; RESISTIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORNI FRUCTUS; DOWN REGULATION; DRUG EFFECT; DRUG ISOLATION; DRUG MEGADOSE; DRUG SCREENING; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; TRADITIONAL MEDICINE;

MUS;

EID: 84885089163     PISSN: 0367326X     EISSN: 18736971     Source Type: Journal    
DOI: 10.1016/j.fitote.2013.03.026     Document Type: Article

References (55)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782-7. (Pubitemid 34000780)
2. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005;12:295-300.
3. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004;10:355-61. (Pubitemid 38508511)
4. Pakala R, Kuchulakanti P, Rha SW, Cheneau E, Baffour R, Waksman R. Peroxisome proliferator-activated receptor gamma: its role in metabolic syndrome. Cardiovasc Radiat Med 2004;5:97-103. (Pubitemid 39349635)
5. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005;26:244-51. (Pubitemid 40603072)
6. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005;54:2460-70. (Pubitemid 41134276)
7. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821-7. (Pubitemid 34000786)
8. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Role of the PPAR family of nuclear receptors in the regulation of metabolic and cardiovascular homeostasis: new approaches to therapy. Curr Opin Pharmacol 2005;5: 177-83. (Pubitemid 40378750)
9. Chinetti-Gbaguidi G, Fruchart JC, Staels B. Therapeutical effects of PPAR agonists assessed by biomarker modulation. Biomarkers 2005;10:S30-6.
10. Yamabe N, Kang KS, Goto E, Tanaka T, Yokozawa T. Beneficial effect of Corni Fructus, a constituent of Hachimi-jio-gan, on advanced glycation end-product-mediated renal injury in streptozotocin-treated diabetic rats. Biol Pharm Bull 2007;30:520-6. (Pubitemid 46355938)
11. Zhang Y, Chen Y, Zhao S. A sedoheptulose gallate from the fruits of Cornus officinalis. Acta Pharmacol Sin 1999;34:153-5.
12. Yamabe N, Kang KS, Matsuo Y, Tanaka T, Yokozawa T. Identification of antidiabetic effect of iridoid glycosides and low molecular weight polyphenol fractions of Corni Fructus, a constituent of Hachimi-jio-gan, in streptozotocin-induced diabetic rats. Biol Pharm Bull 2007;30:1289-96. (Pubitemid 47037654)
13. Yamabe N, Kang KS, Park CH, Tanaka T, Yokozawa T. 7-O-galloyl-D- sedoheptulose is a novel therapeutic agent against oxidative stress and advanced glycation endproducts in the diabetic kidney. Biol Pharm Bull 2009;32:657-64.
14. Park CH, Noh JS, Yamabe N, Kang KS, Tanaka T, Yokozawa T. Beneficial effect of 7-O-galloyl-D-sedoheptulose on oxidative stress and hepatic and renal changes in type 2 diabetic db/db mice. Eur J Pharmacol 2010;640: 233-42.
15. FrühbeckG, Gómez-Ambrosi J, Muruzábal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab 2001;280:E827-47. (Pubitemid 32553225)
16. Sharma K, McCue P, Dunn SR. Diabetic kidney disease in the db/db mouse. Am J Physiol Renal Physiol 2003;284:F1138-44. (Pubitemid 36578440)
17. Yokozawa T, Yamabe N, Kim HY, Kang KS, Hur JM, Park CH, et al. Protective effects of morroniside isolated from Corni Fructus against renal damage in streptozotocin-induced diabetic rats. Biol Pharm Bull 2008;31:1422-8. (Pubitemid 351930661)
18. Naito C, Yamanaka T. Lipid peroxides in atherosclerotic diseases. Nihon Ronen Igakkai Zasshi 1978;15:187-91.
19. Ali SF, LeBel CP, Bondy SC. Reactive oxygen species formation as a biomarker of methylmercury and trimethyltin neurotoxicity. Neurotoxicology 1992;13:637-48.
20. Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957;226: 497-509.
21. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1978;86:271-8. (Pubitemid 9050395)
22. Komatsu S. Extraction of nuclear proteins. Methods Mol Biol 2007;355: 73-7.
23. Derosa G, Salvadeo SA. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol 2008;3:77-84.
24. Viswanadha S, Londos C. Determination of lipolysis in isolated primary adipocytes. Methods Mol Biol 2008;456:299-306.
25. Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41. (Pubitemid 44833742)
26. Vidal-Puig AJ, Considine RV, Jimenez-Liñan M, Werman A, Pories WJ, Caro JF, et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997;99:2416-22. (Pubitemid 27227719)
27. Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med 2003;115:42S-8S.
28. Bünger M, Hooiveld GJ, Kersten S, Müller M. Exploration of PPAR functions by microarray technology-a paradigm for nutrigenomics. Biochim Biophys Acta 2007;1771:1046-64. (Pubitemid 47198550)
29. Bajaj M, Suraamornkul S, Hardies LJ, Glass L, Musi N, DeFronzo RA Effects of peroxisome proliferator-activated receptor (PPAR)-a and PPAR-γ agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Diabetologia 2007;50:1723-31. (Pubitemid 47036647)
30. Lee YA, Cho EJ, Yokozawa T. Effects of proanthocyanidin preparations on hyperlipidemia and other biomarkers in mouse model of type 2 diabetes. J Agric Food Chem 2008;56:7781-9.
31. Harrod JS, Rada CC, Pierce SL, England SK, Lamping KG. Altered contribution of RhoA/Rho kinase signaling in contractile activity of myometrium in leptin receptor-deficient mice. Am J Physiol Endocrinol Metab 2011;301: E362-9.
32. Srikanthan P, Hsueh W. Preventing heart failure in patients with diabetes. Med Clin North Am 2004;88:1237-56. (Pubitemid 39178137)
33. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5. (Pubitemid 38293314)
34. Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. p-Cell failure as a complication of diabetes. Rev Endocr Metab Disord 2008;9:329-43.
35. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 2008;233:4-11.
36. Maritim AC, Sanders RA, Watkins III JB. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003;17:24-38. (Pubitemid 36410972)
37. Rolo AP, Palmeira CM. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. Toxicol Appl Pharmacol 2006;212: 167-78.
38. Nishikawa T, Araki E. Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications. Antioxid Redox Signal 2007;9:343-53. (Pubitemid 46150966)
39. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signaling. Cardiovasc Res 2009;82:9-20.
40. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548-56. (Pubitemid 38766330)
41. Fernández-Sánchez A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á, Esquivel-Chirino C, et al. Inflammation, oxidative stress, and obesity. Int J Mol Sci 2011;12:3117-32.
42. Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adiponectin in obesity-related fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metabol 2009;53:201-12.
43. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007;13:332-9. (Pubitemid 46376688)
44. Yang J, Craddock L, Hong S, Liu ZM. AMP-activated protein kinase suppresses LXR-dependent sterol regulatory element-binding protein-1c transcription in rat hepatoma McA-RH7777 cells. J Cell Biochem 2009;106:414-26.
45. Lee YA, Kim YJ, Cho EJ, Yokozawa T. Ameliorative effects ofproanthocyanidin on oxidative stress and inflammation in streptozotocin- induced diabetic rats. J Agric Food Chem 2007;55:9395-400. (Pubitemid 350205288)
46. de Luca C, Olefsky JM. Inflammation and insulin resistance. FEBS Lett 2008;582:97-105. (Pubitemid 50010731)
47. Guest CB, Park MJ, Johnson DR, Freund GG. The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 2008;13: 5187-94. (Pubitemid 351599668)
48. Ndisang JF. Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediators Inflamm 2010;2010:359732.
49. Kumar NB, Kazi A, Smith T, Crocker T, Yu D, Reich RR, et al. Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol 2010;11:107-17.
50. Shan J, Fu J, Zhao Z, Kong X, Huang H, Luo L, et al. Chlorogenic acid inhibits lipopolysaccharide-induced cyclooxygenase-2 expression in RAW264.7 cells through suppressing NF-κB and JNK/AP-1 activation. Int Immunopharmacol 2009;9:1042-8.
51. Kaneto H, Matsuoka TA, Katakami N, Kawamori D, Miyatsuka T, Yoshiuchi K, et al. Oxidative stress and the JNK pathway are involved in the development of type 1 and type 2 diabetes. Curr Mol Med 2007;7:674-86. (Pubitemid 350201667)
52. Brezniceanu ML, Liu F, Wei CC, Chénier I, Godin N, Zhang SL, et al. Attenuation of interstitial fibrosis and tubular apoptosis in db/db transgenic mice overexpressing catalase in renal proximal tubular cells. Diabetes 2008;57:451-9.
53. Crompton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol 2000;12:414-9. (Pubitemid 30453590)
54. Kashihara N, Sugiyama H, Makino H. Implicationof apoptosisinprogression of renal diseases. Contrib Nephrol 2003;139:156-72.
55. Wagener FA, Dekker D, Berden JH, Scharstuhl A, van der Vlag J. The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 2009;14:1451-8.